Spinoffs and Technology
Co-founded by Dr. Jayachandran Kizhakketadthu (LSI/CBR), ABOzymes is making blood types obsolete by utilizing enzymes from the human microbiome to convert the ABO blood surface antigens to the universal donor blood group.
Co-founded by Dr. Pieter Cullis (LSI) Acuitas is a biotechnology company that works with partners and customers to develop new or improved medicines based on our internationally recognized capabilities in nanotechnology-based pharmaceutical product development.
Co-founded by Dr. Charles Thompson, Andira Medical is dedicated to the advancement of proprietary cannabinoid-based therapeutics for significant unmet-need healthcare indications.
Co-founded by Dr. Yossef Av-Gay, Beyond Air is a Nasdaq traded US clinical stage company using drug-device combination to deliver nitric oxide to treat respiratory diseases.
Co-founded by Dr. Timothy Kieffer, enGene is developing a robust and safe non-viral gene delivery platform targeting mucosal tissues to treat numerous prevalent, chronic diseases such as cancers, diabetes and inflammatory bowel disease. enGene is a clinical stage company with its lead product, EG-70, a next-generation immunotherapy designed to transform outcomes for patients with bladder cancer.
Established by Dr. Yossef Av-Gay, Enox developed proprietary technology that embeds nitric oxide (NO) into polymer based medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. In 2015, Enox was acquired by Clalit Health Care (Israel).
Co-founded by Dr. Pieter Cullis (LSI), Integrated Nanotherapeutics uses proprietary technologies geared towards providing new nanomedicines that are unseen in the market and are both safe and effective to target diseases including cancers and diabetes.
IonsGate Preclinical Services Inc., co-founded by Dr. David Fedida, is a Contract Research Organization (CRO) specializing in preclinical research services focused on cardiac safety pharmacology, drug discovery and ion channel research.
Co-founded by Dr. Steven Hallam, Koonkie Inc., is a bioinformatics consulting company that designs and provides scalable algorithmic and data analytics solutions in the cloud.
Co-founded by Dr. Yossef Av-Gay, Manhattan Solutions aims to develop the next generation immunotherapy by harnessing the natural ability of certain microbes to induce innate immunity.
Co-founded by Dr. Ken Harder, ME Therapeutics Inc. is developing biological and small molecule drugs to target novel pathways involved in cancer-induced immune suppression.
Metamixis (2015) was based on a proprietary platform screening technology, which originated from the Hallam lab, to discover and evolve small molecules and industrial catalysts from uncultivated microbial communities inhabiting natural and engineered ecosystems. Its technology has now been purchased by Gingko Bioworks.
Co-founded by Dr. William Mohn, Microbiome Insights is a Vancouver-based service company providing microbiome analysis for academic and industrial researchers. We have the systems and expertise that you need to add cutting edge microbiome analysis to your study.
Developed by Dr. Franck Duong, the Peptidisc technology allows capture of membrane proteins into water soluble peptidiscs to enable discoveries on membrane proteins and for downstream antibody & drug development.
Precision Nanosystems' technology enables manufacturing of novel nanoparticles that are used for cell-specific delivery of research tools, diagnostic imaging agents, and drugs to study, diagnose and treat disease. The technology enables development of nanomedicines faster and at lower cost.
RhYme (for Rhodoccocal Enzymology) was founded by Dr. Lindsay Eltis, Dr. James Round (a former trainee in the Eltis lab) and Mr. Raphael Roccor (current trainee in the Eltis lab) to develop and commercialize a microbial fermentation technology created at UBC.
Based upon technologies from the LSI laboratories of Drs. Don Brooks and Jayachandran Kizhakkedathu, Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues, initially targeting oncology indications including bladder and ovarian cancer.